Brief: Blueprint Medicines To Regain Global Rights To GAVRETO (Pralsetinib) From Roche
23/02/2023 16:18
Feb 23 (Reuters) - Blueprint Medicines Corp BPMC.O :
* BLUEPRINT MEDICINES TO REGAIN GLOBAL RIGHTS TO GAVRETO®
(PRALSETINIB) FROM ROCHE
* BLUEPRINT MEDICINES CORP - WILL REGAIN GLOBAL
COMMERCIALIZATION
& DEVELOPMENT RIGHTS TO GAVRETO(PRALSETINIB), EXCLUDING GREATER
CHINA
Source text for Eikon: ID:nPn38RRR7a
Further company coverage: BPMC.O
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G